News Details - novonordisk.com
WEB1 day ago · About Wegovy® (semaglutide 2.4 mg) In the EU, Wegovy ® is indicated as an adjunct to a reduced calorie diet and increased physical activity for weight management in adults with a BMI of 30 kg/m 2 or greater (obesity), or adults with a BMI of 27 kg/m 2 or greater (overweight) in the presence of at least one weight-related comorbid condition ...
European Drug Agency Supports Novo Nordisk's Blockbuster …
WEB7 hours ago · The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for an update of Novo Nordisk A/S’ (NYSE:NVO) Wegovy (semaglutide 2.4 ...
What the results of Wegovy’s longest clinical trial yet show about ...
WEBMay 13, 2024 · More than 25,000 people in the US are starting Wegovy every week, drugmaker Novo Nordisk said this month. And in a KFF poll released Friday, 6% of respondents said they were currently using a...
Novo Nordisk’s Wegovy Gets EU Backing to Treat Obesity …
WEB19 hours ago · Novo Nordisk said European regulators support the use of its blockbuster weight-loss drug Wegovy to help reduce heart failure in obese patients. The Danish pharmaceutical giant said late Thursday ...
News Details - Novo Nordisk
WEBWegovy® approved in the US for cardiovascular risk reduction in people with overweight or obesity and established cardiovascular disease. Bagsværd, Denmark, 8 March 2024 – Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved a label expansion for Wegovy ® based on a supplemental New Drug Application ...
News details - Novo Nordisk
WEBMar 8, 2024 · Wegovy® receives FDA approval for cardiovascular risk reduction in adults with known heart disease and overweight or obesity. Wegovy® (semaglutide) injection 2.4 mg is the first-and-only medicine indicated for both reduction of the risk of major adverse cardiovascular events (MACE) such as death, heart attack, or stroke and for long-term ...
News details - Novo Nordisk
WEBPLAINSBORO, N.J., June 4, 2021 /PRNewswire/ -- Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved the new drug application (NDA) for Wegovy ™ (semaglutide) injection 2.4 mg, the first-and-only prescription weight-loss medication with once-weekly dosing.
News details - Novo Nordisk
WEBNov 11, 2023 · Novo Nordisk has filed for a label update of Wegovy ® in the US and EU to include an indication for reducing the risk of major adverse cardiovascular events (cardiovascular death, non-fatal heart attack or non-fatal stroke) in people with an initial BMI of 27 kg/m 2 or greater and established cardiovascular disease (CVD). A decision is ...
News Details - Novo Nordisk
WEBNov 11, 2021 · Wegovy™ is a once-weekly semaglutide 2.4 mg injection for chronic weight management in adults living with obesity (initial BMI≥30 kg/m 2) or overweight (initial BMI≥27 kg/m 2) with at least one weight-related comorbidity such as high blood pressure, heart disease or type 2 diabetes.
Wegovy Cuts Risk of Heart Problems, Novo Nordisk Trial Says
WEBAug 8, 2023 · A new obesity drug, Wegovy, slashed the risk of serious heart problems by 20 percent in a large trial, the drug’s maker said on Tuesday, a finding that could challenge the perception of weight...
Skip to content